This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mondesire, W. H. Articles by Meric-Bernstam, F. Search for Related Content PubMed PubMed Citation Articles by Mondesire, W. H. Articles by Meric-Bernstam, F.

Targeting Mammalian Target of Rapamycin Synergistically Enhances Chemotherapy-Induced Cytotoxicity in Breast Cancer Cells

Departments of ¹ Surgical Oncology, ² Biostatistics, ³ Molecular and Cellular Oncology, and ⁴ Molecular Therapeutics, The University of Texas M. D. Anderson Cancer Center, Houston, Texas; and ⁵ The University of Texas Houston Graduate School of Biomedical Sciences, Houston, Texas

Purpose: The serine-threonine kinase mammalian target of rapamycin has emerged as a potential target for cancer therapy. Rapamycin and rapamycin analogs are undergoing clinical trials and have induced clinical responses in a subgroup of patients. Rapamycin has also been reported to enhance the efficacy of several cytotoxic agents. The aim of this study was to determine the nature of the interactions between rapamycin and chemotherapeutic agents used as first- and second-line agents against breast cancer.

Experimental Design: We performed a multiple drug effect/combination index isobologram analysis in cells sensitive and resistant to rapamycin alone in vitro, and we evaluated the in vivo efficacy of combination therapy in a rapamycin-sensitive model.

Results: In vitro, synergistic interactions were observed in combinations with paclitaxel, carboplatin, and vinorelbine. Additive effects were observed in combinations with doxorubicin and gemcitabine. Rapamycin dramatically enhanced paclitaxel- and carboplatin-induced apoptosis. This effect was sequence dependent and mediated at least partly through caspase activation. Furthermore, rapamycin enhanced chemosensitivity to paclitaxel and carboplatin in HER2/neu-overexpressing cells, suggesting a potential approach to these poorly behaving tumors. Cell lines that are resistant to the growth-inhibitory effect of rapamycin were also resistant to rapamycin-mediated chemosensitization. In vivo, rapamycin combined with paclitaxel resulted in a significant reduction in tumor volume compared with either agent alone in rapamycin-sensitive tumors.

Conclusions: Rapamycin potentiates the cytotoxicity of selected chemotherapeutic agents in cell lines sensitive to the effects of rapamycin due to aberrations in the phosphatidylinositol 3'-kinase/Akt pathway, suggesting that combination therapy may be effective in patients selected for aberrations in this pathway.

This article has been cited by other articles:

				A. Soni, A. Akcakanat, G. Singh, D. Luyimbazi, Y. Zheng, D. Kim, A. Gonzalez-Angulo, and F. Meric-Bernstam eIF4E knockdown decreases breast cancer cell growth without activating Akt signaling Mol. Cancer Ther., July 1, 2008; 7(7): 1782 - 1788. [Abstract] [Full Text] [PDF]

				A. Moreno, A. Akcakanat, M. F Munsell, A. Soni, J. C Yao, and F. Meric-Bernstam Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors Endocr. Relat. Cancer, March 1, 2008; 15(1): 257 - 266. [Abstract] [Full Text] [PDF]

				F. Andre, R. Nahta, R. Conforti, T. Boulet, M. Aziz, L. X. H. Yuan, F. Meslin, M. Spielmann, G. Tomasic, L. Pusztai, et al. Expression patterns and predictive value of phosphorylated AKT in early-stage breast cancer Ann. Onc., February 1, 2008; 19(2): 315 - 320. [Abstract] [Full Text] [PDF]

				S. Yoon, M.-Y. Lee, S. W. Park, J.-S. Moon, Y.-K. Koh, Y.-H. Ahn, B.-W. Park, and K.-S. Kim Up-regulation of Acetyl-CoA Carboxylase {alpha} and Fatty Acid Synthase by Human Epidermal Growth Factor Receptor 2 at the Translational Level in Breast Cancer Cells J. Biol. Chem., September 7, 2007; 282(36): 26122 - 26131. [Abstract] [Full Text] [PDF]

				M Beeram, Q-T. Tan, R. Tekmal, D Russell, A Middleton, and L. deGraffenried Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling Ann. Onc., August 1, 2007; 18(8): 1323 - 1328. [Abstract] [Full Text] [PDF]

				S. Mabuchi, D. A. Altomare, M. Cheung, L. Zhang, P. I. Poulikakos, H. H. Hensley, R. J. Schilder, R. F. Ozols, and J. R. Testa RAD001 Inhibits Human Ovarian Cancer Cell Proliferation, Enhances Cisplatin-Induced Apoptosis, and Prolongs Survival in an Ovarian Cancer Model Clin. Cancer Res., July 15, 2007; 13(14): 4261 - 4270. [Abstract] [Full Text] [PDF]

				C.-T. Chiang, T.-D. Way, and J.-K. Lin Sensitizing HER2-overexpressing cancer cells to luteolin-induced apoptosis through suppressing p21WAF1/CIP1 expression with rapamycin Mol. Cancer Ther., July 1, 2007; 6(7): 2127 - 2138. [Abstract] [Full Text] [PDF]

				D. Marimpietri, C. Brignole, B. Nico, F. Pastorino, A. Pezzolo, F. Piccardi, M. Cilli, D. Di Paolo, G. Pagnan, L. Longo, et al. Combined Therapeutic Effects of Vinblastine and Rapamycin on Human Neuroblastoma Growth, Apoptosis, and Angiogenesis Clin. Cancer Res., July 1, 2007; 13(13): 3977 - 3988. [Abstract] [Full Text] [PDF]

				T. L. Phung, G. Eyiah-Mensah, R. K. O'Donnell, R. Bieniek, S. Shechter, K. Walsh, C. Kuperwasser, and L. E. Benjamin Endothelial Akt Signaling Is Rate-Limiting for Rapamycin Inhibition of Mouse Mammary Tumor Progression Cancer Res., June 1, 2007; 67(11): 5070 - 5075. [Abstract] [Full Text] [PDF]

				M. F. McCarty and K. I. Block Preadministration of High-Dose Salicylates, Suppressors of NF-{kappa}B Activation, May Increase the Chemosensitivity of Many Cancers: An Example of Proapoptotic Signal Modulation Therapy. Integr Cancer Ther, September 1, 2006; 5(3): 252 - 268. [Abstract] [PDF]

				B. Spankuch, S. Heim, E. Kurunci-Csacsko, C. Lindenau, J. Yuan, M. Kaufmann, and K. Strebhardt Down-regulation of Polo-like Kinase 1 Elevates Drug Sensitivity of Breast Cancer Cells In vitro and In vivo Cancer Res., June 1, 2006; 66(11): 5836 - 5846. [Abstract] [Full Text] [PDF]

				R. Namba, L. J.T. Young, C. K. Abbey, L. Kim, P. Damonte, A. D. Borowsky, J. Qi, C. G. Tepper, C. L. MacLeod, R. D. Cardiff, et al. Rapamycin Inhibits Growth of Premalignant and Malignant Mammary Lesions in a Mouse Model of Ductal Carcinoma In situ Clin. Cancer Res., April 15, 2006; 12(8): 2613 - 2621. [Abstract] [Full Text] [PDF]

				S. J. Isakoff, J. A. Engelman, H. Y. Irie, J. Luo, S. M. Brachmann, R. V. Pearline, L. C. Cantley, and J. S. Brugge Breast Cancer-Associated PIK3CA Mutations Are Oncogenic in Mammary Epithelial Cells Cancer Res., December 1, 2005; 65(23): 10992 - 11000. [Abstract] [Full Text] [PDF]

				A. D. Basso, A. Mirza, G. Liu, B. J. Long, W. R. Bishop, and P. Kirschmeier The Farnesyl Transferase Inhibitor (FTI) SCH66336 (lonafarnib) Inhibits Rheb Farnesylation and mTOR Signaling: ROLE IN FTI ENHANCEMENT OF TAXANE AND TAMOXIFEN ANTI-TUMOR ACTIVITY J. Biol. Chem., September 2, 2005; 280(35): 31101 - 31108. [Abstract] [Full Text] [PDF]

				J. Dong, J. Peng, H. Zhang, W. H. Mondesire, W. Jian, G. B. Mills, M.-C. Hung, and F. Meric-Bernstam Role of Glycogen Synthase Kinase 3{beta} in Rapamycin-Mediated Cell Cycle Regulation and Chemosensitivity Cancer Res., March 1, 2005; 65(5): 1961 - 1972. [Abstract] [Full Text] [PDF]